title: Control of human fascioliasis by selective chemotherapy: design, cost and effect of the first public health, school-based intervention implemented in endemic areas of the Nile Delta, Egypt.
abstract: Human fascioliasis is becoming a serious public health problem with a number of endemic areas identified in different countries. The viability of humans as definitive hosts has been experimentally demonstrated, and there is now a need to control the human infection along with the veterinary infection. In 1998, following reports on high prevalence among children in the Nile Delta, the Egyptian Ministry of Health and Population launched the first public health, school-based intervention to control human fascioliasis. An innovative selective treatment approach, with chemotherapy targeted to specific high risk age groups and villages, was adopted. First, high prevalence districts were identified by a regional baseline survey, then screening and selective treatment of all schoolchildren took place in high prevalence villages within those districts. From 1998 to 2002 the programme screened almost 36000 schoolchildren, in six districts, treating 1280 cases of human fascioliasis. Prevalence in the endemic area was reduced from 5.6 to 1.2%. The control intervention is described in detail, including data on cost. The targeted, selective chemotherapy approach was appropriate in addressing low prevalence infection, effective in reducing prevalence rates and transmission of the disease, and in the present situation, more cost-effective than mass distribution.
authors.affiliation: Directorate General for Development Cooperation, Ministry of Foreign Affaires, Italian Embassy, Cairo, Egypt. curtale@asplazio.it
authors.forename: Filippo
authors.initials: F
authors.lastname: Curtale
authors.forename: Yehia Abd El Wahab
authors.initials: YA
authors.lastname: Hassanein
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Savioli
mesh_terms: D000871:Anthelmintics / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D002648:Child; D003362:Cost-Benefit Analysis; D004534:Egypt / Q000453:epidemiology; D019353:Endemic Diseases / Q000517:prevention & control* / Q000706:statistics & numerical data; D005211:Fascioliasis / Q000453:epidemiology / Q000517:prevention & control*; D005243:Feces / Q000469:parasitology; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D008403:Mass Screening; D010270:Parasite Egg Count; D015995:Prevalence; D015397:Program Evaluation; D011634:Public Health / Q000191:economics*; D012572:School Health Services / Q000191:economics / Q000458:organization & administration*; D000077682:Triclabendazole
chemical_list: D000871:Anthelmintics; D001562:Benzimidazoles; D000077682:Triclabendazole